雾化吸入肝素治疗急性肺损伤的研究进展  

Research Progress of Nebulized Heparin for Acute Lung Injury

作　　者：胡彬[1,2] 陈桂良[3] 王浩[2] HU Bin CHEN Gui-liang WANG Hao(School of Pharmacy, Fudan University, Shanghai 201203, China Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai 201203, China Shang- hai Institute for Food and Drug Control, Shanghai 201203, China)

机构地区：[1]复旦大学药学院,上海201203 [2]中国医药工业研究总院上海医药工业研究院,上海201203 [3]上海市食品药品检验所,上海201203

出　　处：《中国药学杂志》2017年第4期258-262,共5页Chinese Pharmaceutical Journal

摘　　要：肺泡纤维沉积是急性肺损伤的主要特征,吸入抗凝疗法治疗急性肺损伤被认为可通过减轻气道纤维沉积和阻塞而改善肺功能,并且可提高局部生物利用度而增强药效,降低全身出血性并发症发生的风险。肝素是临床上使用最为广泛的抗凝药物,笔者对国内外采用雾化吸入肝素治疗烟雾吸入、严重感染以及机械通气导致的急性肺损伤的临床前研究和临床研究进行了系统的综述。目前的研究表明,雾化吸入肝素治疗急性肺损伤是非常有前景的治疗方案。It is widely recognized that alveolar fibrin deposition is a hallmark of acute lung injury. The inhaled anticoagulation regimens are employed to manage acute lung injury with the goal of improving lung function by decreasing airways fibrin deposition and obstruction. Inhalation administration may improve local biological availability and efficacy and lower the risk of systemic bleeding complications. Heparin is the most widely used anticoagulant in clinic. The author performed a systematic review of international preclinical studies and clinical trials of nebulized heparin for acute lung injury induced by smoke inhalation,severe infection and mechanical ventilation in animals and humans. It was demonstrated that nebulized heparin is a very prospective regimen in the treatment of acute lung injury.

关 键 词：雾化吸入肝素 急性肺损伤 乙酰半胱氨酸 

分 类 号：R974[医药卫生—药品]